Hangzhou Sumgen Biotech
Hangzhou Sumgen Biotech is a China-based biotechnology company running 2 late-stage cancer trials of SG2918 and SG301 in multiple myeloma.
Overview
Hangzhou Sumgen Biotech, based in Hangzhou, China, is a biotechnology company. Sumgen Biotech is a biotech company focused on innovative drug development in oncology, specialising in antibody drugs including monoclonal antibodies and antibody-drug conjugates. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing SG2918 and SG301 in multiple myeloma. The largest, NCT06508983 (A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients), plans to enrol 360 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Scorecard
All companies- phase 3 +3
- targets +2
- modalities +2
Similar pages
not linked directly; found by shared links- CompanyChongqing Precision Biotech
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyCelltrion
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyShanghai AbelZeta
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyNanjing Leads Biolabs
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanySinocelltech
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyQilu Pharmaceutical
Shares Multiple myeloma and the tag ctgov-sponsor.
- TargetCD38
Shares SG301, Multiple myeloma.